Results 121 to 130 of about 199,597 (317)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Clinical Association of Pan-Immune-Inflammation Value with MEFV Mutation Burden and Amyloidosis in Adults with Familial Mediterranean Fever: A Retrospective Cohort Study [PDF]

Özgür Yılmaz, Osman Erinc, Ozan Cemal İçaçan, Gulseren Goktolga Erkoca, Recep Demirci, Şengül Aydın Yoldemir, Murat Akarsu   +6 more
openalex   +1 more source

eTable2 from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer [PDF]

, 2023
Romualdo Barroso‐Sousa, Tanya E. Keenan, Sònia Pernas, Pedro Exman, Esha Jain, Ana C. Garrido-Castro, Melissa E. Hughes, Brittany Bychkovsky, Renato Umeton, Janet Files, Neal I. Lindeman, Laura E. MacConaill, F. Stephen Hodi, Ian E. Krop, Deborah Dillon, Eric P. Winer, Nikhil Wagle, Nancy U. Lin, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Sara M. Tolaney   +20 more
openalex   +1 more source

Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma

BMC Medical Genomics
Background Pathway mutations have been calculated to predict the poor prognosis and immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC).
Yuhong Huang, Han Liu, Bo Liu, Xiaoyan Chen, Danya Li, Junyuan Xue, Nan Li, Lei Zhu, Liu Yang, Jing Xiao, Chao Liu   +10 more
doaj   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma

Frontiers in Immunology
ObjectiveThis study is aimed to develop multivariate prediction method in colorectal cancer (CRC) diagnosis.MethodologyM3 gene expression was determined using Fecal DNA extraction kits and performed by qRT-PCR.
Junyue Xu, Shuai Chen, Shuai Chen, Hongxia Niu, Yahong Zhao, Xiaohong Wu, Yi Li, Shana Zhang, Shana Zhang   +8 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy

, 2020
Katherine I. Zhou, Bryan Peterson, Anthony V. Serritella, Joseph Thomas, Natalie Reizine, Stephanie Moya, Carol Tan, Yan Wang, Daniel V.T. Catenacci   +8 more
openalex   +2 more sources

Supplemental Figure 2 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers

, 2023
Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann   +14 more
openalex   +1 more source